LLY Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Eli Lilly and Company (NYSE: LLY)
›
Eli Lilly and Company (NYSE: LLY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 50,000 employees.
The shares were at 1351.20 USD on 19 November 2026, up 32.2% over 52 weeks. Its 52-week range is 850.51 USD to 1475.25 USD: the price is 8.4% below the high and 58.9% above the low.
At a market capitalisation of 1.20T USD, it trades at 43.9 times trailing earnings and 26.6 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 72% for LLY. It pays a dividend yielding 0.50% (it pays out 22% of its earnings), against a median of 2.55% among the dividend payers in that peer group.
Eli Lilly and Company reports return on equity of 77.8%, an operating margin of 51.3% and revenue up 38.6% year over year.
Its debt exceeds its cash by 44.62B USD, a debt-to-equity ratio of 1.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 29 analysts cover the stock, with an average rating of Buy; their mean price target of 1468.57 USD is 8.7% above the current price. The next earnings report is expected on 3 February 2027.